Monday, March 13, 2023 5:52:47 PM
It's been a bit painful to see the stock in a slow but very constant drift down. IMO it's well worth considering that sales of the C preferreds have removed a significant amount from the demand side of the market trading because those purchases are made directly from the company and fund the company rather than being part of the balance of buyers and sellers in open market trading. 885k Cs equivalent to 22M common shares were purchased in Q4. That's a lot of demand to remove from the open market for the stock considering that an average day's trading in less than 1.5M shares. Enough to have a visible impact on the open market for the shares.
On the one hand sale of the Cs have provided equity funding to the company at very good terms and very low cost which is great! But at the same time, taking that demand for shares out of the market trading, IMO has also clearly had the downside effect of tilting the open market supply/demand balance hence putting constant downward pressure on the stock to whatever extent that sales of the C preferreds has been non-trivial on an ongoing basis.
A few posters here have posited that buyers of series C shares were flipping, i.e. selling common shares and replacing them with C shares because the C shares were being sold at a small discount to market. I doubt that very much. Several reasons: only accredited investors can buy the preferred C shares. That means people with steady annual income of over $200k or assets in excess of $1M excluding home equity. I believe that these individuals are likely to be investors, not petty traders. Also I spoke to one accredited investor who was offered a price for the C shares that was less than 5% below daily closing price. He said there was no way the discount was enough to cover the risks of trying to sell a large number of common shares and then use the proceeds to buy the preferred.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM